Country: Canada
Language: English
Source: Health Canada
TRANEXAMIC ACID
MARCAN PHARMACEUTICALS INC
B02AA02
TRANEXAMIC ACID
500MG
TABLET
TRANEXAMIC ACID 500MG
ORAL
15G/50G
Prescription
HEMOSTATICS
Active ingredient group (AIG) number: 0114760001; AHFS:
APPROVED
2020-02-13
_Page 1 of 21 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MAR-TRANEXAMIC ACID Tranexamic acid Tablets, BP Tablet, 500 mg, Oral BP Anti-fibrinolytic agent Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112, Ottawa, ON, K2E 1A2 Date of Initial Authorization: FEB 13, 2020 Date of Revision: June 9, 2022 Submission Control Number: 260172 _Page 2 of 21 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 06/2022 7 WARNINGS AND PRECAUTIONS 06/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES................................................................................................ 2 TABLE OF CONTENTS ................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION........................................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ...................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ...................................................................................... 5 4.1 Dosing Considerations ............................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment................................................................ 5 4.5 Missed Dose............................................................................................................. 5 5 OVERDOSAGE ....................................................................................... Read the complete document